|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||211.66 - 216.50|
|52-week range||1.33 - 216.50|
|PE ratio (TTM)||6.23|
|Earnings date||4 Jul 2018 - 9 Jul 2018|
|Forward dividend & yield||0.02 (1.07%)|
|1y target est||N/A|
Syncona, a leading healthcare company focused on investing in and building global leaders in life science, is pleased to note that its portfolio company Blue Earth Diagnostics (Blue Earth) has signed a license for radiohybrid PSMA-targeted agent, rhPSMA-7, from Scintomics GmbH, Germany, a specialist in radiopharmaceuticals and radiopharmaceutical technologies. The move expands Blue Earth’s oncology portfolio, representing an opportunity to extend its leading position in prostate cancer imaging, including potential new areas of high unmet need, such as early stage primary prostate cancer patients.
Syncona Limited (a closed-ended investment company incorporated in Guernsey with registration number 55514) Monthly Fact Sheet February 2018 Attached is a link to the February 2018 Monthly Fact Sheet ...
Syncona Limited LEI: 213800X8MBI5VQITLW60 Notification of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs") and Connected Persons 18 January 2018 1. Details of PDMR / ...
Syncona Limited (a closed-ended investment company incorporated in Guernsey with registration number 55514) Monthly Fact Sheet October 2017 Attached is a link to the October 2017 Monthly Fact Sheet for ...
Syncona Limited (a closed-ended investment company incorporated in Guernsey with registration number 55514) Monthly Fact Sheet September 2017 Attached is a link to the September 2017 Monthly Fact Sheet ...
Syncona Ltd (“Syncona”), a leading healthcare company focused on investing in and building global leaders in life science, today notes that its portfolio company Nightstar Therapeutics plc (“Nightstar”) has today announced the closing of its previously announced initial public offering in the United States of 6,164,000 American Depositary Shares (“ADSs”) representing 6,164,000 ordinary shares, at an initial public offering price of $14.00, which includes an additional 804,000 ADSs issued upon the exercise in full by the underwriters of their option to purchase additional ADSs. All of the ADSs were offered by Nightstar.